

Novel models for studying prostate cancer biology

Poster Session 12

Saturday, 12 March
14:15 - 15:45

Location: Room Vienna (Hall B2, level 0)

Chairs: M. Puhr, Innsbruck (AT)
J.A. Schalken, Nijmegen (NL)
G. Van Der Pluijm, Leiden (NL)

Aims and objectives of this presentation

Novel animal and cellular models have been extensively used in prostate cancer research. Because of the heterogeneity of human prostate cancer, it is particularly important to demonstrate applicability of these novel models to address clinically relevant questions. Mediators of stromal epithelial interactions and respective signaling pathways will be discussed.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

14:38 - 14:48

Introduction

G. Van Der Pluijm, Leiden (NL)

136

Periprostatic adipose tissue acts as a driving force for the local invasion of prostate cancer in obesity: Role of the CCR3/CCL7 axis

By: Roumiguie M.¹, Laurent V.², Toulet A.², Zaidi F.³, Valet P.⁴, Mazerolles C.³, Malavaud B.¹, Muller C.²

Institutes:¹Institut Universitaire Du Cancer, Dept. of Urology, Toulouse, France, ²Institut De Pharmacologie Et Biologie Structurale Du CNRS, Dept. of Oncology, Toulouse, France, ³Institut Universitaire Du Cancer, Dept. of Pathology, Toulouse, France, ⁴INSERM, U1048, Toulouse, France

137

The neurosteroidogenic potential of metastatic prostate cancer cell lines under starvation treatment with abiraterone

By: Gomes De Mello Martins A.G.¹, Allegretta G.¹, Haupenthal J.¹, Eberhard J.¹, Van Der Zee J.², Unteregger G.², Stöckle M.², Junker K.², Hartmann R.W.¹, Ohlmann C-H.²

Institutes:¹Helmholtz Institute For Pharmaceutical Research Saarland, Dept. of Drug Design and Optimization, Saarbrücken, Germany, ²Saarland University Medical Center, Dept. of Urology, Homburg-Saar, Germany

138

Exploring a novel therapeutic target for neuroendocrine prostate cancer using a xenograft model of trans-differentiation

By: Akamatsu S.¹, Wyatt A.², Lin D.², Lysakowski S.², Zhang F.², Kawai Y.², Fazli L.², Ogawa O.¹, Lotan T.³, Rubin M.⁴, Beltran H.⁵, Zoubeidi A.², Wang Y.², Gleave M.², Collins C.²

Institutes:¹Kyoto University Graduate School of Medicine, Dept. of Urology, Kyoto, Japan, ²Vancouver Prostate Centre, Dept. of Urologic Sciences, Vancouver, Canada, ³Johns Hopkins School of Medicine, Dept. of Pathology, Baltimore, United States of America, ⁴Weil Cornell Medical College, Dept. of Pathology and Laboratory Medicine, New York, United States of America, ⁵Weil Cornell Medical College, Dept. of Medicine, New York, United States of America

139

Prostate cancer xenograft in vitro culture using organoid technology

By: Nicholson C.², Williams E.², Vela L.¹

Institutes:¹Princess Alexandra Hospital/Australian Prostate Cancer Research Centre-Queensland, Dept. of Urology, Woolloongabba, Australia, ²Queensland University of Technology, Australian Prostate Cancer Research Centre - Queensland, Woolloongabba, Australia

- 140 **Orthotopic xenografts using LuCaP136 spheroid cultures provide a versatile preclinical model of prostate cancer**
By: Linxweiler J.¹, Körbel C.², Valta M.³, Müller A.⁴, Junker K.¹, Stöckle M.¹, Menger M.D.², Peehl D.M.⁵, Saar M.¹
Institutes:¹Saarland University Medical Center, Dept. of Urology, Homburg/Saar, Germany, ²Saarland University Medical Center, Dept. of Clinical-Experimental Surgery, Homburg/Saar, Germany, ³Turku University Hospital and University of Turku, Dept. of Medicine, Turku, Finland, ⁴Saarland University Medical Center, Dept. of Diagnostic and Interventional Radiology, Homburg/Saar, Germany, ⁵Stanford University School of Medicine, Dept. of Urology, Stanford, United States of America
- 141 **Development of prostate intra-epithelial neoplasia in an aging series of PolgA mutator mice suggests a role for mitochondrial DNA mutations in prostate carcinogenesis**
By: Sachdeva A.¹, El-Sherif A.², Turnbull D.³, Greaves L.³, Heer R.¹
Institutes:¹Newcastle University, Northern Institute of Cancer Research, Newcastle upon Tyne, United Kingdom, ²Newcastle-Upon-Tyne NHS Foundation Trust, Dept. of Histopathology, Newcastle upon Tyne, United Kingdom, ³Newcastle University, Wellcome Trust Centre For Mitochondrial Research, Newcastle upon Tyne, United Kingdom
- 142 **Next generation sequencing to determine the clonal origin of lymph node metastasis in multifocal prostate cancer: Defining the biologically dominant nodule**
By: Salami S.¹, Hovelson D.², Mathieu R.³, Susani M.⁴, Rioux-Leclercq N.⁵, Tracey J.¹, Shariat S.³, Tomlins S.², Palapattu G.¹
Institutes:¹University of Michigan, Dept. of Urology, Ann Arbor, United States of America, ²University of Michigan, Dept. of Pathology, Ann Arbor, United States of America, ³Medical University Vienna, Dept. of Urology, Vienna, Austria, ⁴Medical University Vienna, Dept. of Pathology, Vienna, Austria, ⁵Rennes University Hospital, Dept. of Pathology, Rennes, France
- 143 **MED15 overexpression arises during androgen deprivation therapy via PI3K/mTOR signaling**
By: Offermann A.¹, Shaikhibrahim Z.¹, Syring I.², Vogel W.¹, Ruiz C.³, Zellweger T.⁴, Rentsch C.A.⁵, Bubendorf L.³, Perner S.¹
Institutes:¹University Hospital of Luebeck and Leibniz Research Center Borstel, Dept. of Pathology, Lübeck, Germany, ²University Hospital of Bonn, Dept. of Urology and Pediatric Urology, Bonn, Germany, ³University Hospital Basel, Institute for Pathology, Basel, Switzerland, ⁴St. Claraspital Basel, Dept. of Urology, Basel, Switzerland, ⁵University Hospital Basel, Dept. of Urology, Basel, Switzerland
- 144 **Expression of glucocorticoid receptors, androgen receptors and its splice variants in prostate cancer: Comparison between hormone dependent and castrate-resistant prostate cancer**
By: Shim M.¹, Choi S.K.², Kim Y.², Ahn T.Y.², Ahn H.²
Institutes:¹Hallym University Sacred Heart Hospital, Dept. of Urology, Anyang-Si, South Korea, ²Asan Medical Center, University of Ulsan College of Medicine, Dept. of Urology, Seoul, South Korea
- 145 **Tumour-stromal architecture influences prognosis and response to docetaxel in prostate cancer**
By: Bokobza S.², Hiew K.¹, Huby R.², Davies E.², Brown M.¹, Barry S.², Davies B.², Elliott T.³, Clarke N.⁴, Smith N.²
Institutes:¹Cancer Research UK Manchester Institute, The University of Manchester, Genito Urinary Cancer Research Group, Manchester, United Kingdom, ²AstraZeneca, R & D, Oncology IMed, Macclesfield, United Kingdom, ³Christie Hospital NHS Foundation Trust, Dept. of Oncology, Manchester, United Kingdom, ⁴Christie Hospital NHS Foundation Trust, Dept. of Urology, Manchester, United Kingdom
- 146 **Patient-derived three-dimensional spheroid cultures provide an innovative tool for comprehensive in-vitro studies on organ-confined prostate cancer**
By: Saar M.¹, Linxweiler J.¹, Muhs S.¹, Ohlmann C.H.¹, Jung V.¹, Pryalukhin A.², Junker K.¹, Stöckle M.¹
Institutes:¹Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg/Saar, Germany, ²Saarland University Medical Center, Dept. of Pathology, Homburg/Saar,

Germany

147

The C-Myc and TNF α /NF- κ B pathways are critically involved in the regulatory network between the undifferentiated prostate basal stem cell state and the more differentiated luminal prostate epithelial cells

By: Höfner T.¹, Klein C.², Eisen C.², Rigo-Watermeier T.², Haferkamp A.³, Trumpp A.², Sprick M.²

Institutes:¹University Hospital Frankfurt, Heidelberg Institute for Stem Cell Research and Experimental Medicine (HI-STEM), German Cancer Research Center (DKFZ), Frankfurt am Main, Germany, ²German Cancer Research Center (DKFZ), Heidelberg Institute for Stem Cell Research and Experimental Medicine (HI-STEM), Heidelberg, Germany, ³University Hospital Frankfurt, Dept. of Urology, Frankfurt am Main, Germany